[go: up one dir, main page]

MX369444B - REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG. - Google Patents

REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG.

Info

Publication number
MX369444B
MX369444B MX2014010387A MX2014010387A MX369444B MX 369444 B MX369444 B MX 369444B MX 2014010387 A MX2014010387 A MX 2014010387A MX 2014010387 A MX2014010387 A MX 2014010387A MX 369444 B MX369444 B MX 369444B
Authority
MX
Mexico
Prior art keywords
differentiation
mediated
peripheral neuropathies
peripheral nerves
igg
Prior art date
Application number
MX2014010387A
Other languages
English (en)
Other versions
MX2014010387A (es
Inventor
Schwarz Hans-Peter
Kuery Patrick
Tzekova Nevena
Hartung Hans-Peter
Hermann Corinna
Maria Reipert Birgit
Ehrlich Hartmut
Bunk Sebastian
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2014010387A publication Critical patent/MX2014010387A/es
Publication of MX369444B publication Critical patent/MX369444B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

La presente invención se refiere a la capacidad de la IgG policlonal de promover la maduración, diferenciación y producción de mielina de las cédulas de Schwann. Se proporcionan métodos para tratar neuropatías periféricas desmielinizantes no idiopáticas en mamíferos, donde .la neuropatía no está mediada por el sistema inmunitario o medida por infección, a través de la administración de IgG policlonal. Los tipos de neuropatía periférica desmielinizante que se pueden tratar con la presente invención incluyen traumatismo de nervios periféricos y neuropatías periféricas inducidas por toxina. De manera alternativa, una composición de IgG policlonal puede aplicarse directamente a una célula nerviosa periférica para inducir la maduración, diferenciación en un estado mielinizante y expresión de mielina o promover la supervivencia celular.
MX2014010387A 2012-02-29 2013-02-28 REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG. MX369444B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Publications (2)

Publication Number Publication Date
MX2014010387A MX2014010387A (es) 2015-09-25
MX369444B true MX369444B (es) 2019-11-08

Family

ID=47884569

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010387A MX369444B (es) 2012-02-29 2013-02-28 REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG.
MX2019012496A MX2019012496A (es) 2012-02-29 2014-08-28 Remielinizacion de nervios perifericos estimulada por igg.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012496A MX2019012496A (es) 2012-02-29 2014-08-28 Remielinizacion de nervios perifericos estimulada por igg.

Country Status (21)

Country Link
US (5) US8986670B2 (es)
EP (2) EP2820042B1 (es)
JP (3) JP6335800B2 (es)
KR (3) KR102673154B1 (es)
CN (4) CN107551269A (es)
AR (2) AR090211A1 (es)
AU (3) AU2013203088B2 (es)
BR (1) BR112014021240A2 (es)
DK (2) DK3590960T3 (es)
EA (2) EA032000B1 (es)
ES (2) ES2755056T3 (es)
FI (1) FI3590960T3 (es)
HK (2) HK1206035A1 (es)
IL (3) IL274512B2 (es)
MX (2) MX369444B (es)
NZ (1) NZ629867A (es)
PL (2) PL3590960T3 (es)
PT (2) PT2820042T (es)
SG (1) SG11201405302WA (es)
TW (3) TW201838654A (es)
WO (1) WO2013130826A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
WO2020146370A1 (en) * 2019-01-07 2020-07-16 Mallinckrodt Ard Ip Limited Methods of promoting remyelination

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3473407D1 (en) 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
AU8649391A (en) * 1990-08-15 1992-03-17 University Of Miami Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AU6653094A (en) 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
PT1084147E (pt) 1998-06-09 2005-01-31 Statens Seruminstitut Processo para producao de imunoglobulinas para administracao intravenosa e outros produtos de imunoglobulina
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
MXPA02011163A (es) * 2000-05-10 2004-08-19 Mayo Foundation Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central.
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
US20050069541A1 (en) 2003-01-24 2005-03-31 Karlik Stephen J. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
KR20070009995A (ko) 2004-01-30 2007-01-19 수오멘 푸나이넨 리스티 베리팔베루 바이러스 안전성 면역글로불린을 제조하는 방법
BRPI0508096B8 (pt) 2004-02-27 2021-05-25 Octapharma Ag método de preparação de um preparado de anticorpo seguro purificado contra vírus e vírus inativado
MX2009008178A (es) * 2007-02-02 2009-10-26 Biogen Idec Inc Uso de semaforina 6a para promover la mielinizacion y la diferenciacion de oligodendrocitos.
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法

Also Published As

Publication number Publication date
US20180291087A1 (en) 2018-10-11
CN110343171A (zh) 2019-10-18
BR112014021240A2 (pt) 2018-09-18
DK3590960T3 (da) 2023-04-24
MX2019012496A (es) 2020-01-20
AU2013203088A1 (en) 2013-09-19
PT3590960T (pt) 2023-04-18
US20200216518A1 (en) 2020-07-09
MX2014010387A (es) 2015-09-25
NZ629867A (en) 2016-09-30
FI3590960T3 (fi) 2023-04-25
KR20220045087A (ko) 2022-04-12
PT2820042T (pt) 2019-10-31
HK1206035A1 (en) 2015-12-31
IL234303B (en) 2020-09-30
AU2013203088B2 (en) 2015-12-03
AR090211A1 (es) 2014-10-29
KR102170615B1 (ko) 2020-10-28
AU2016201137A1 (en) 2016-03-10
JP6979990B2 (ja) 2021-12-15
US10494418B2 (en) 2019-12-03
HK1248534A1 (zh) 2018-10-19
CN107551269A (zh) 2018-01-09
DK2820042T3 (da) 2019-10-28
IL274512A (en) 2020-06-30
US8986670B2 (en) 2015-03-24
EP3590960B1 (en) 2023-03-29
SG11201405302WA (en) 2014-09-26
PL3590960T3 (pl) 2023-07-17
TWI700297B (zh) 2020-08-01
IL277103A (en) 2020-10-29
KR20140134690A (ko) 2014-11-24
EP3590960A1 (en) 2020-01-08
ES2943585T3 (es) 2023-06-14
AU2016201137B2 (en) 2017-10-12
JP2018030856A (ja) 2018-03-01
KR102673154B1 (ko) 2024-06-05
CN109966488A (zh) 2019-07-05
US9834593B2 (en) 2017-12-05
TW201736398A (zh) 2017-10-16
TW201838654A (zh) 2018-11-01
US20130224150A1 (en) 2013-08-29
JP6637934B2 (ja) 2020-01-29
AU2018200026A1 (en) 2018-01-25
IL274512B2 (en) 2024-07-01
EP2820042A2 (en) 2015-01-07
US20210300997A1 (en) 2021-09-30
AU2018200026B2 (en) 2019-12-05
KR20200126005A (ko) 2020-11-05
PL2820042T3 (pl) 2020-03-31
JP6335800B2 (ja) 2018-05-30
JP2015508824A (ja) 2015-03-23
TW201400502A (zh) 2014-01-01
WO2013130826A3 (en) 2013-12-05
WO2013130826A2 (en) 2013-09-06
TWI632158B (zh) 2018-08-11
AR117207A2 (es) 2021-07-21
US20150232536A1 (en) 2015-08-20
EP2820042B1 (en) 2019-07-24
EA201892521A1 (ru) 2019-07-31
IL274512B1 (en) 2024-03-01
ES2755056T3 (es) 2020-04-21
CN104302666A (zh) 2015-01-21
EA201400966A1 (ru) 2014-12-30
JP2020059705A (ja) 2020-04-16
EA032000B1 (ru) 2019-03-29

Similar Documents

Publication Publication Date Title
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
IN2014DN07384A (es)
TW200942552A (en) Combination therapy with c-Met and HER antagonists
PH12016501470A1 (en) Crystalline forms of an androgen receptor modulator
AU2011328009A8 (en) Compounds and methods for treating pain
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MX2015012072A (es) Esteres de glicopirrolato anticolinergico para el tratamiento de hiperhidrosis.
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
AU2018200026B2 (en) IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
SG10201914117QA (en) Treatment Of Myelosuppression
MX2014002990A (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
AU2018205186B2 (en) Angiotensin in treating brain conditions
GB2489382A (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
MY196111A (en) Suspension Compositions of Cyclosporin a for Subconjunctival and Periocular Injection
AU2012283449A8 (en) Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
IN2014DN09826A (es)
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
MX359343B (es) Proceso para la preparación de (1r,4r)-6´-fluoro-(n,n-dimetil- y n-metil)-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexano-1,1´-pirano -[3,4,b]indol]-4-amina.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration